Bussiness Overview

Pipelines

NanoCarriers business consists of five pipelines for pharmaceutical development and two products currently under in-house research which are considered potential pipelines.
Currently, two pipelines are in the stage of clinical study and one pipeline is in the stage of nonclinical study. These three products contain existing promising anticancer agents or analogous compounds encapsulated in micellar nanoparticles. The risk of development is relatively lower than that of new chemical compounds. NanoCarrier aims to expand the business of these pipelines globally.

Products under development
Main Pipelines
Product Indication Region for
clinical studies		 Developmental stage
Stage Status
Paclitaxel Micelle
(NK105)(Note 1)		 Gastric cancer Japan Phase II
clinical study
  • Licenced to Nippon Kayaku Co. Ltd. for exclusively for Japan and Asia.
  • No prophylactic medication to reduce adverse reactions, have been observed in phase I clinical study.
  • Phase II clinical study started on November 2007.
Nanoplatin®
(NC-6004)		 Pancreatic cancer Taiwan Phase I/II clinical study
  • Phase I study and ended at March 2008 by NanoCarrier, in the United Kingdom.
  • NanoCarrier granted to OEP an exclusive license for commercialization in the territory of East Asia (excluding Japan and Main China), South-East Asia and Oceania to start the next step clinical study.
  • IND was approved in December 2008.(Taiwan)
  • Nanocarrier and OEP operated the study in Asia for pancreatic cancer.
DACH-Platin Micelle
(NC-4016)
(Note 2)		 Cancer
(Note 3)		 Europe Phase I clinical study
  • Licensed to Debiopharm S.A. for worldwide excluding Japan.
  • Debiopharm operates the sutudy in UK and France.

New pipelines
Product Indication Region for clinical studies Developmental stage
Stage
Protein Micelle Not decided
(Note 4)		 - Feasibility Study
siRNA Micelle Not decided
(Note 4)		 - Feasibility Study
Sensor Linked Micelle Cancer
(Note 3)		 - Feasibility Study
pH-Sensitive Micelle Cancer
(Note 3)		 - Feasibility Study completed.
Docetaxel Micelle Cancer
(Note 3)		 - Feasibility Study completed.
(Note 1) NK105 is the product development code used for this product at Nippon Kayaku Co., Ltd.
(Note 2) NC-4016 is NanoCarrier’s product development code. The product development code used at Debiopharm S.A. is Debio 0507.
(Note 3) DACH-Platin Micelle (NC-4016), Sensor Linked Micelle, pH-Sensitive Micelle, and Docetaxel Micelle are indicated for cancer, but the type(s) of cancer is currently not specified. Specific indications are expected to be determined following future progress in research and development, before the start of phase II clinical studies.
(Note 4) Protein Micelle and siRNA Micelle are currently not indicated for specific diseases because indications will differ depending on the type of product encapsulated in micellar nanoparticles.
Pagetop